By Josh White
Date: Tuesday 29 Oct 2024
(Sharecast News) - Shield Therapeutics reported a strong third-quarter performance for its iron deficiency treatment Accrufer in the US on Tuesday, achieving net revenue of $7.2m.
By Josh White
Date: Wednesday 25 Sep 2024
(Sharecast News) - Shield Therapeutics announced promising results from its phase three paediatric clinical trial for 'Accrufer' and 'Ferracru', or ferric maltol, in treating iron deficiency anaemia (IDA) in children on Wednesday.
By Josh White
Date: Tuesday 27 Aug 2024
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Tuesday that 'ACCRUFeR', or ferric maltol, had been approved by Health Canada as a prescription drug for the treatment of adults with iron deficiency anaemia (IDA).
Currency | UK Pounds |
Share Price | 2.95p |
Change Today | 0.28p |
% Change | 10.28 % |
52 Week High | 7.65p |
52 Week Low | 1.23p |
Volume | 40,674,235 |
Shares Issued | 782.06m |
Market Cap | £23.07m |
Beta | 1.88 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:30 | 50,000 @ 2.95p |
16:25 | 500,000 @ 3.23p |
16:24 | 250,000 @ 2.90p |
16:17 | 33,878 @ 2.94p |
16:16 | 15,000 @ 2.94p |
You are here: research